CAGE Bio Reports P-II Study Results of CGB-500 for the Treatment of Atopic Dermatitis
Shots:
- The randomized, vehicle-controlled P-II study evaluating the safety and efficacy of CGB-500, an ionic liquid formulation of 1% tofacitinib in patients with AD
- The study met all 1EPs & 2EPs i.e., patients achieved an average reduction of 98% in lesional EASI scores vs 28% in the vehicle group at 8wks., treatment success (rating of clear or almost clear with ≥ 2-grade improvement from baseline) was achieved (95% vs 24%), >90% improvement in EASI score (EASI-90), reduction of ≥4 on NRS for itching 84% vs 43%
- The therapy was well tolerated with no TEAEs and no reports of pain or skin irritation at the application site. The company seeks to initiate dose-ranging & registration trials to validate the efficacy & safety of CGB-500
Ref: CAGE Bio | Image: CAGE Bio
Related News:- Alphyn Biologics Reports Interim Results from P-IIa Clinical Trial of AB-101a for Atopic Dermatitis with Secondary Bacterial Infection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
